.. Et-techniques, , p.41

.. Les-Émetteurs-de-positons, , p.41

.. Principe-de-la-détection, , p.41

T. Correction-d-'atténuation, , p.42

E. Evènements-fortuits, , p.42

T. Quantification-en, , p.43

F. , , p.44

.. Mécanisme-de-fixation, , p.44

F. Cinétique-de-la-18, , p.45

.. Protocole-d-'acquisition, , p.45

.. Répartition-physiologique-du-traceur, , p.45

D. , , p.47

M. Et and M. , , p.49

.. Critères-d-'inclusion, , p.49

T. Acquisition, , p.49

R. Analyse-des, , p.50

P. , , p.50

.. Analyse-des-performances-diagnostiques, , p.50

.. Analyse-de-l-'impact-thérapeutique, , p.51

T. Analyse-de-la, 1. Tdm-À-la, and .. Et-de-la-osseuse, , p.52

.. Analyse-statistique, , p.52

R. , , p.53

.. Population-Étudiée, , p.53

.. Intérêt-de-l-'acquisition-au-temps-précoce, , p.53

D. Performances, , p.55

P. Taux-de and T. Statut-de-la, , p.55

R. and .. , , p.56

.. Résultats-selon-la-localisation, , p.58

.. Résultats-au-niveau-ganglionnaire, , p.59

.. Résultats-au-niveau-osseux, , p.60

.. Résultats-en-fonction-des-traitements, , p.60

.. Selon-les-traitements-antérieurs, , p.61

.. Impact-thérapeutique, , p.62

T. Analyse-de-la, . Tdm, S. De-la, and O. , , p.64

.. Enseignements-À-tirer-pour-la-pratique-clinique, , p.65

.. Intérêt-de-l-'acquisition-au-temps-précoce, , p.65

.. Interprétation-des-ganglions-médiastinaux, , p.66

F. Interprétation-des, , p.67

D. , , p.69

C. , , p.74

B. , , p.75

F. Rozet, C. Hennequin, J. Beauval, P. Beuzeboc, L. Cormier et al., CCAFU french national guidelines 2016-2018 on prostate cancer]. Progres En Urol J Assoc Francaise Urol Soc Francaise Urol, pp.95-143, 2016.

. Inca, Epidemiologie nationale du cancer de la prostate-données essentielles Disponibles sur https://lesdonneesecancerfr/les-fiches-de-synthese/1-types-cancer/10- cancer-prostate/19-epidemiologie-cancer-prostate-france-metropolitaineessentielleshtlm- ind4, 2012.

A. Heidenreich, P. Bastian, J. Bellmunt, M. Bolla, S. Joniau et al., EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent???Update 2013, European Urology, vol.65, issue.1, pp.124-161, 2014.
DOI : 10.1016/j.eururo.2013.09.046

M. Quinn and P. Babb, Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons, BJU International, vol.9, issue.2, pp.162-73, 2002.
DOI : 10.1002/sim.4780090506

, Numéro thématique ? Chlordécone aux Antilles : bilan actualisé des risques sanitaires http://www.invs.sante, BEH, pp.3-4, 2011.

T. Seisen, M. Rouprêt, A. Faix, and S. Droupy, The prostate gland: a crossroad between the urinary and the seminal tracts], Progres En Urol J Assoc Francaise Urol Soc Francaise Urol. 2012, vol.22, issue.1, pp.2-6

J. Mcneal, The zonal anatomy of the prostate. The Prostate, pp.35-49, 1981.

J. Mcneal, Normal Histology of the Prostate, The American Journal of Surgical Pathology, vol.12, issue.8, pp.619-652, 1988.
DOI : 10.1097/00000478-198808000-00003

, Cancer de la prostate (Guide affection de longue durée) HAS, HAS, 2012.

J. Epstein, M. Amin, V. Reuter, and P. Humphrey, Contemporary Gleason Grading of Prostatic Carcinoma, International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, 2014.
DOI : 10.1097/PAS.0000000000000820

S. Freedland, M. Terris, G. Csathy, C. Kane, C. Amling et al., PREOPERATIVE MODEL FOR PREDICTING PROSTATE SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY USING PERCENT OF BIOPSY TISSUE WITH CANCER, BIOPSY GLEASON GRADE AND SERUM PROSTATE SPECIFIC ANTIGEN, The Journal of Urology, vol.171, issue.6, pp.2215-2235, 2004.
DOI : 10.1097/01.ju.0000124463.13319.0a

G. Kristiansen, L. Egevad, M. Amin, B. Delahunt, J. Srigley et al., The 2014 consensus conference of the ISUP on Gleason grading of prostatic carcinoma]. Pathol. 2016 Feb, pp.17-26

G. Andriole, E. Crawford, R. Grubb, S. Buys, D. Chia et al., Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up, JNCI Journal of the National Cancer Institute, vol.341, issue.sep14_1, pp.125-157, 2012.
DOI : 10.1136/bmj.c4543

A. Heidenreich, C. Ohlmann, and S. Polyakov, Anatomical Extent of Pelvic Lymphadenectomy in Patients Undergoing Radical Prostatectomy, European Urology, vol.52, issue.1, pp.29-37, 2007.
DOI : 10.1016/j.eururo.2007.04.020

I. Latorzeff, J. Mazurier, C. Boutry, P. Dudouet, P. Richaud et al., Benefit of intensity modulated and image-guided radiotherapy in prostate cancer], Cancer Radiother J Soc Francaise Radiother Oncol, vol.14, pp.6-7479, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00909914

L. Salomon, D. Azria, C. Bastide, P. Beuzeboc, L. Cormier et al., Recommandations en Onco-Urologie 2010 : Cancer de la prostate, Progr??s en Urologie, vol.20, issue.4, pp.217-251, 2010.
DOI : 10.1016/S1166-7087(10)70042-7

K. Fizazi, H. Scher, A. Molina, C. Logothetis, K. Chi et al., Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, The Lancet Oncology, vol.13, issue.10, pp.983-92, 2012.
DOI : 10.1016/S1470-2045(12)70379-0

J. Park, C. Kim, S. Park, B. Park, H. Lee et al., Prostate Cancer: Role of Pretreatment Multiparametric 3-T MRI in Predicting Biochemical Recurrence After Radical Prostatectomy, American Journal of Roentgenology, vol.202, issue.5, pp.459-465, 2014.
DOI : 10.2214/AJR.13.11381

L. Evangelista, F. Zattoni, A. Guttilla, G. Saladini, F. Zattoni et al., Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer, Clinical Nuclear Medicine, vol.38, issue.5, pp.305-319, 2013.
DOI : 10.1097/RLU.0b013e3182867f3c

H. Awwad, J. Geisel, and R. Obeid, The role of choline in prostate cancer, Clinical Biochemistry, vol.45, issue.18, pp.1548-53, 2012.
DOI : 10.1016/j.clinbiochem.2012.08.012

T. Hara, N. Kosaka, and H. Kishi, PET imaging of prostate cancer using carbon-11-choline, J Nucl Med Off Publ Soc Nucl Med, vol.39, issue.6, pp.990-995, 1998.

T. Degrado, R. Coleman, S. Wang, S. Baldwin, M. Orr et al., Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer, Cancer Res, vol.61, issue.1, pp.110-117, 2001.

E. Verwer, D. Oprea-lager, A. Van-den-eertwegh, R. Van-moorselaar, A. Windhorst et al., Quantification of 18F-Fluorocholine Kinetics in Patients with Prostate Cancer, Journal of Nuclear Medicine, vol.56, issue.3, pp.365-71
DOI : 10.2967/jnumed.114.148007

URL : http://jnm.snmjournals.org/content/56/3/365.full.pdf

D. Rietbergen, B. Van-der-hiel, W. Vogel, and M. Stokkel, Mediastinal lymph node uptake in patients with prostate carcinoma on F18-choline PET/CT, Nuclear Medicine Communications, vol.32, issue.12, pp.1143-1150, 2011.
DOI : 10.1097/MNM.0b013e32834b76fa

D. Oprea-lager, A. Vincent, R. Van-moorselaar, W. Gerritsen, A. Van-den-eertwegh et al., Dual-Phase PET-CT to Differentiate [18F]Fluoromethylcholine Uptake in Reactive and Malignant Lymph Nodes in Patients with Prostate Cancer, PLoS ONE, vol.154, issue.2, p.48430, 2012.
DOI : 10.1371/journal.pone.0048430.t003

URL : https://doi.org/10.1371/journal.pone.0048430

T. Degrado, R. Reiman, D. Price, S. Wang, and R. Coleman, Pharmacokinetics and radiation dosimetry of 18F-fluorocholine, J Nucl Med Off Publ Soc Nucl Med, 2002.

M. Brambilla, C. Secco, M. Dominietto, R. Matheoud, G. Sacchetti et al., Performance characteristics obtained for a new 3-dimensional lutetium oxyorthosilicate-based wholebody PET/CT scanner with the National Electrical Manufacturers Association NU 2-2001 standard, J Nucl Med Off Publ Soc Nucl Med, vol.46, issue.12, pp.2083-91, 2005.

M. Defrise, P. Kinahan, D. Townsend, C. Michel, M. Sibomana et al., Exact and approximate rebinning algorithms for 3-D PET data, IEEE Transactions on Medical Imaging, vol.16, issue.2, 1997.
DOI : 10.1109/42.563660

M. Beheshti, W. Langsteger, and I. Fogelman, Prostate Cancer: Role of SPECT and PET in Imaging Bone Metastases, Seminars in Nuclear Medicine, vol.39, issue.6, pp.396-407, 2009.
DOI : 10.1053/j.semnuclmed.2009.05.003

S. Chondrogiannis, M. Marzola, G. Grassetto, A. Maffione, L. Rampin et al., New acquisition protocol of 18F-choline PET/CT in prostate cancer patients: review of the literature about methodology and proposal of standardization, BioMed Res Int, vol.2014, p.215650, 2014.

A. Bakhsh, Y. Venel, M. Courtehoux, S. Maia, C. Perault et al., TEP/TDM ?? la 18-fluorocholine dans le cancer de prostate??: quel protocole d???acquisition???, M??decine Nucl??aire, vol.40, issue.4, pp.307-321, 2016.
DOI : 10.1016/j.mednuc.2016.03.140

M. Umbehr, M. Müntener, T. Hany, T. Sulser, and L. Bachmann, The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis, European Urology, vol.64, issue.1, pp.106-123
DOI : 10.1016/j.eururo.2013.04.019

S. Nitsch, O. Hakenberg, M. Heuschkel, D. Dräger, G. Hildebrandt et al., Evaluation of Prostate Cancer with 11C- and 18F-Choline PET/CT: Diagnosis and Initial Staging, Journal of Nuclear Medicine, vol.57, issue.Supplement_3, pp.38-42, 2016.
DOI : 10.2967/jnumed.115.169748

URL : http://jnm.snmjournals.org/content/57/Supplement_3/38S.full.pdf

J. Pinaquy, D. Clermont-galleran, H. Pasticier, G. Rigou, G. Alberti et al., Comparative effectiveness of [(18) F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer. The Prostate, Feb, vol.1575, issue.3, pp.323-354, 2015.

L. Evangelista, A. Guttilla, F. Zattoni, P. Muzzio, and F. Zattoni, Utility of Choline Positron Emission Tomography/Computed Tomography for Lymph Node Involvement Identification in Intermediate- to High-risk Prostate Cancer: A Systematic Literature Review and Meta-analysis, European Urology, vol.63, issue.6, pp.1040-1048
DOI : 10.1016/j.eururo.2012.09.039

M. Umbehr, M. Müntener, T. Hany, T. Sulser, and L. Bachmann, The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis, European Urology, vol.64, issue.1, pp.106-123
DOI : 10.1016/j.eururo.2013.04.019

M. Beheshti, S. Haim, R. Zakavi, M. Steinmair, P. Waldenberger et al., Impact of 18F-Choline PET/CT in Prostate Cancer Patients with Biochemical Recurrence: Influence of Androgen Deprivation Therapy and Correlation with PSA Kinetics, Journal of Nuclear Medicine, vol.54, issue.6, pp.833-873, 2013.
DOI : 10.2967/jnumed.112.110148

M. Marzola, S. Chondrogiannis, A. Ferretti, G. Grassetto, L. Rampin et al., Role of 18F-Choline PET/CT in Biochemically Relapsed Prostate Cancer After Radical Prostatectomy, Clinical Nuclear Medicine, vol.38, issue.1, pp.26-32, 2013.
DOI : 10.1097/RLU.0b013e318266cc38

M. Mccarthy, T. Siew, A. Campbell, N. Lenzo, N. Spry et al., 18F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging, European Journal of Nuclear Medicine and Molecular Imaging, vol.168, issue.Suppl 2, pp.14-22, 2011.
DOI : 10.1148/radiology.199.3.8638000

A. Toledano, R. Chiche, H. Lamallem, A. Kanoui, S. Beley et al., ??l??vation du PSA apr??s irradiation prostatique??: rebond ou r??cidive biologique???, Progr??s en Urologie, vol.18, issue.9, 2008.
DOI : 10.1016/j.purol.2008.06.001

S. Kwee, M. Coel, and J. Lim, Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging, Annals of Nuclear Medicine, vol.32, issue.Suppl 1, 2012.
DOI : 10.1097/MNM.0b013e32834b76fa

V. Graute, N. Jansen, C. Ubleis, M. Seitz, M. Hartenbach et al., Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy, European Journal of Nuclear Medicine and Molecular Imaging, vol.35, issue.Suppl 1, pp.271-82, 2012.
DOI : 10.1007/s00259-008-0716-2

M. Picchio, A. Briganti, S. Fanti, A. Heidenreich, B. Krause et al., The Role of Choline Positron Emission Tomography/Computed Tomography in the Management of Patients with Prostate-Specific Antigen Progression After Radical Treatment of Prostate Cancer, European Urology, vol.59, issue.1, pp.51-60, 2011.
DOI : 10.1016/j.eururo.2010.09.004

R. Dost, A. Glaudemans, A. Breeuwsma, and I. De-jong, Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.35, issue.2, pp.41-47
DOI : 10.1007/s00259-007-0552-9

J. Soyka, M. Muster, D. Schmid, B. Seifert, U. Schick et al., Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.47, issue.6, pp.936-979
DOI : 10.1016/j.eururo.2011.07.060

URL : http://www.zora.uzh.ch/id/eprint/62296/4/PaperArztdaten_Soyka_EJNM_revised_10.01.2012-1.pdf